METTLER TOLEDO Thornton M800 and M300 ISM process analytical instrumentation provides reliable, accurate measurements of conductivity/resistivity, pH/ORP, dissolved oxygen and dissolved ozone. On-board digital measurement and Intelligent Sensor Management (ISM) technology provide the utmost in convenience and control of sensor performance.
Gilead Sciences has signed a 10-year collaboration deal worth up to $1.97bn with Arcus Biosciences to co-develop and co-commercialise the current and future cancer therapeutic product candidates in the latter's pipeline.
Merck has agreed to acquire Themis Bioscience, an Austrian pharma company, which is currently engaged in developing a vaccine for COVID-19.
Shionogi has agreed to acquire clinical-stage biotechnology company Tetra Therapeutics in a deal valued at around $500m.
Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76m in an oversubscribed Series B offering that closed on Monday, May 18, 2020.
Rallybio, a biopharma company based in Connecticut, has raised $145m in a Series B financing round led by Pivotal bioVenture Partners, for developing therapies for severe and rare disorders.
Boehringer Ingelheim and CDR-Life announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA).
Catalent has collaborated with speciality pharmaceutical company Ennaid Therapeutics for the development of an oral and antiviral treatment for Covid-19 disease.
Moderna has secured fast track designation from the US Food and Drug Administration (FDA) for its mRNA-1273, the mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2).
Acer Therapeutics has joined forces with the US National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for Covid-19 patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.